Drug intelligence / Profile preview

ampiroxicam

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Ampiroxicam is a prodrug of piroxicam, a nonsteroidal anti-inflammatory drug (NSAID). It is designed to be converted into piroxicam in the body after administration. Like piroxicam, it is intended for the relief of pain and inflammation associated with conditions such as osteoarthritis and rheumatoid arthritis. The prodrug formulation aims to reduce gastrointestinal side effects compared to direct administration of piroxicam[1][2][3]. The mechanism of action involves inhibition of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the production of prostaglandins that mediate pain, fever, and inflammation[4].

Other names: Ampiroxicam

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on ampiroxicam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampiroxicam.

Explore the full profile